Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib for Relapsed or Refractory T-cell Prolymphocytic Leukemia
NCT01162031Phase 2Withdrawn
- Sponsor
- Stanford University
- Start
- Jun 2010
- Primary completion
- Jul 2011
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in T-cell prolymphocytic leukemia (T-PLL), sponsored by Stanford University. Primary endpoint: Overall Response Rate at 1 year. Planned start Jun 2010; status: withdrawn.
02
Drugs
bortezomib
03
Conditions
T-cell prolymphocytic leukemia (T-PLL)
Beyond the preview
Go deeper on NCT01162031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01162031.